on what matters most to the system, and those areas where NICE is internationally acknowledged as the expert and that provide the greatest benefit to people using health and care services. We will do this through a focus on our


priority areas. For example, we are working to provide earlier assessments of value to identify the most promising medtech, diagnostics and digital products - to support them to develop the further evidence required. Additionally, we aim to expand our capacity for technology appraisal guidance for medicines by 20% through


DUB AI 2023


developing a more proportionate approach. The usefulness and usability of our guidelines will be improved by developing digital living guideline recommendations in a non-Covid topic, with a new model of support for adoption of best practice. Finally, NICE is starting an internal transformation of the way we work, including our processes, technology and culture in order to support and deliver on the first 3 priorities.


You can find out more and subscribe to our newsletters, at www.nice.org.uk/life-sciences.


UKHEALT HCAREPA VILION. COM 25


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58